BioXcel Therapeutics Files 8-K: Other Events
Ticker: BTAI · Form: 8-K · Filed: Jul 15, 2025 · CIK: 1720893
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
BioXcel filed an 8-K for 'Other Events' - need to see what's up.
AI Summary
On July 15, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not elaborated upon in the provided text. The company is incorporated in Delaware and its principal executive offices are located at 555 Long Wharf Drive, New Haven, CT.
Why It Matters
This filing signals a material event has occurred for BioXcel Therapeutics, requiring disclosure to investors. The nature of the 'Other Event' could impact the company's operations or stock.
Risk Assessment
Risk Level: medium — The filing of an 8-K for 'Other Events' suggests a potentially significant development that could impact the company's valuation, but the lack of specific details in the provided text creates uncertainty.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- July 15, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 555 Long Wharf Drive (address) — Principal executive offices
- New Haven (city) — Location of principal executive offices
- CT (state) — State of principal executive offices
- 06511 (zip_code) — Zip code of principal executive offices
FAQ
What specific event is being reported under 'Other Events'?
The provided text does not specify the details of the 'Other Events' reported in the 8-K filing.
When was the earliest event reported?
The earliest event reported was on July 15, 2025.
What is BioXcel Therapeutics, Inc.'s state of incorporation?
BioXcel Therapeutics, Inc. is incorporated in Delaware.
Where are BioXcel Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
What is the company's telephone number?
The company's telephone number is (475) 238-6837.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 15, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).